logo
Share SHARE
FONT-SIZE Plus   Neg

MorphoSys Reports First Results From Phase 1 Study With Lanthipeptide MOR107

MorphoSys AG (MPSYY.PK) announced the completion of the first part of a phase 1 clinical study in healthy volunteers with the investigational drug candidate MOR107 ahead of schedule.

MOR107 is a selective agonist of the angiotensin II receptor type 2 (AT2-R), and is a lanthipeptide based on the proprietary technology platform of MorphoSys's subsidiary Lanthio Pharma. MOR107 is also the first lanthipeptide in MorphoSys's clinical pipeline.

Based on an initial analysis of subjects enrolled to date, in all doses tested in this first-in-human trial, based on blinded data, there were no clinically relevant safety events seen, and all adverse events observed thus far were mild and transient in nature. Moreover a dose-dependent pharmacokinetic profile for MOR107 was observed.

The study has been conducted by MorphoSys's fully owned subsidiary Lanthio Pharma B.V., Groningen, Netherlands.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Amazon has slashed the price of 4K movies and tv shows, probably to compete with launch offer of Apple TV 4K that plans to sell 4K content at the rate of HD content. The 4K version of its set-top box is expected to be in market next week. The Securities and Exchange Commission or SEC announced Monday its two new initiatives aimed to address cyber-based threats and protect retail investors. SEC announced the creation of a Cyber Unit to focus the Enforcement Division's substantial cyber-related expertise on targeting cyber-related misconduct. The agency also established a retail strategy task force. China has largely blocked instant messaging service WhatsApp, the media reported. The disruption is said to be the latest step to tighten censorship as the country prepares for the Communist Party's congress in Beijing, which starts October 18.
comments powered by Disqus
Follow RTT